ArrayExpress Uploaderarrayexpress_sidhumanNEG49NEGRDIVPOS62POSRDIIICPOS24POSRDIIICNEG54NEGRDIIICPOS72POSRDIIBNEG55NEGRDIIICNEG61NEGRDIIICPOS48POSRDIIIANEG39NEGRDIIICNEG50POSRDIIIANEG44NEGRDIIANEG51NEGRDIIBNEG61POSRDIIBNEG30NEGRDIIIBNEG52NEGRDIIIANEG69NEGRDIIANEG56POSRDIIICNEG73NEGRDIIAPOS47POSRDIIICNEG41NEGRDIIICPOS49POSRDIIAPOS28POSRDIIIBNEG57NEGRDIIANEG46NEGPCRIIICPOS30POSPCRnot specifiedNEG65NEGPCRIIBPOS52POSPCRIIIBNEG56NEGPCRIIBNEG46NEGPCRIIICPOS56POSPCRIIIANEG53NEGPCRIIBNEG62NEGPCRIIICNEG55NEGPCRIIANEG51NEGPCRIIIBPOS53POSPCRIIIANEG41NEGPCRIIICNEG50POSPCRIIIANEG63POSPCRIIANEG38POSPCRINEG43NEGPCRIIIANEG51NEGPCRIIICNEG45NEGPCRIIICPOS56NEGPCRIIIANEG47NEGPCRIIANEG36NEGPCRIPOS38POSPCRIIANEG30NEGPCRIIIANEG52NEGPCRIIIBNEG34NEGPCRIIANEG50NEGPCRIIA124503We identified a 17-gene Her2-enriched tumor initiating cell (HTIC) signature in MMTV-Her2/Neu mouse mammary TICs. Here, we show that...E-GEOD-37946/profile/8773/arrayexpressuploader550breastbreast cancercancercellDec.12, 2014FalseE-GEOD-37946_A-AFFY-33her2-enriched-tumor-initiating-cell-htic-genomic-pHER2-enriched tumor initiating cell (HTIC) genomic predictor of response following neoadjuvant trastuzumab-based chemotherapy in HER2+ breast cancerJun.18, 2014We identified a 17-gene Her2-enriched tumor initiating cell (HTIC) signature in MMTV-Her2/Neu mouse mammary TICs. Here, we show that patients with HTICS+ HER2+:ERα− tumors are more likely to achieve a pathologic complete response to trastuzumab-based neoadjuvant chemotherapy compared with HER2+:ER+ tumors. Neoadjuvant study of 50 HER2-positive breast cancer cases treated with trastuzumab-based chemotherapy pre-operatively. Pre-treatment FNA from primary tumors were obtained and RNA extracted and hybridized to Affymetrix microarrays according to manufacturer protocol. Pathologic response was assessed at the end of neoadjuvant treatment.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-37946http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-37946/samples/